From the *Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; †Department of Cardiac Surgery, Vita-Salute San Raffaele University, Milan, Italy; ‡Department of Anesthesia and Intensive Care, Academician EN Meshalkin Novosibirsk State Budget Research Institute of Circulation Pathology, Novosibirsk, Russia; and §Department of Anesthesia, Mexico Hospital, San Josè, Costa Rica.
Anesth Analg. 2017 Mar;124(3):743-752. doi: 10.1213/ANE.0000000000001609.
To better understand the role of acute normovolemic hemodilution (ANH) in a surgical setting with high risk of bleeding, we analyzed all randomized controlled trials (RCTs) in the setting of cardiac surgery that compared ANH with standard intraoperative care. The aim was to assess the incidence of ANH-related number of allogeneic red blood cell units (RBCu) transfused. Secondary outcomes included the rate of allogeneic blood transfusion and estimated total blood loss.
Twenty-nine RCTs for a total of 2439 patients (1252 patients in the ANH group and 1187 in the control group) were included in our meta-analysis using PubMed/MEDLINE, Cochrane Controlled Trials Register, and EMBASE.
Patients in the ANH group received fewer allogeneic RBCu transfusions (mean difference = -0.79; 95% confidence interval [CI], -1.25 to -0.34; P = .001; I = 95.1%). Patients in the ANH group were overall transfused less with allogeneic blood when compared with controls (356/845 [42.1%] in the ANH group versus 491/876 [56.1%] in controls; risk ratio = 0.74; 95% CI, 0.62 to 0.87; P < .0001; I = 72.5%), and they experienced less postoperative blood loss (388 mL in ANH versus 450 mL in control; mean difference = -0.64; 95% CI, -0.97 to -0.31; P < .0001; I = 91.8%).
ANH reduces the number of allogeneic RBCu transfused in the cardiac surgery setting together with a reduction in the rate of patients transfused with allogeneic blood and with a reduction of bleeding.
为了更好地理解急性等容血液稀释(ANH)在高出血风险的手术环境中的作用,我们分析了心脏手术环境中所有比较 ANH 与标准术中护理的随机对照试验(RCT)。目的是评估与 ANH 相关的异体红细胞单位(RBCu)输注数量。次要结局包括异体输血率和估计总失血量。
我们使用 PubMed/MEDLINE、Cochrane 对照试验登记处和 EMBASE 对 29 项 RCT 进行了荟萃分析,共纳入 2439 例患者(ANH 组 1252 例,对照组 1187 例)。
ANH 组患者接受的异体 RBCu 输注量较少(平均差=-0.79;95%置信区间[CI],-1.25 至-0.34;P=.001;I=95.1%)。与对照组相比,ANH 组患者总体异体输血较少(ANH 组 356/845[42.1%],对照组 491/876[56.1%];风险比=0.74;95%CI,0.62 至 0.87;P<.0001;I=72.5%),术后失血也较少(ANH 组 388 mL,对照组 450 mL;平均差=-0.64;95%CI,-0.97 至-0.31;P<.0001;I=91.8%)。
ANH 可减少心脏手术中异体 RBCu 的输注数量,降低异体输血率和出血率。